Form 4: IMMX CEO Buys Shares in Pre-Planned Transaction

Immix Biopharma's CEO and Chairman, Ilya M. Rachman, purchased 746 shares of common stock at $6.67 per share as part of a Rule 10b5-1 plan.

Summary

• Ilya M. Rachman, CEO and Chairman of Immix Biopharma, Inc. (IMMX), acquired 746 shares of common stock.
• The transaction occurred on December 10, 2025, at a price of $6.67 per share.
• This purchase was made pursuant to a Rule 10b5-1 pre-arranged trading plan.
• Following this transaction, Mr. Rachman directly beneficially owns 1,141,683 shares of Immix Biopharma common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the CEO and Chairman's purchase of company stock, which generally signals confidence in the company's future. The transaction being part of a 10b5-1 plan suggests a pre-meditated investment rather than a reactive one.

Positives

• The CEO and Chairman's purchase of company stock can be interpreted as a vote of confidence in the company's future prospects.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned investment strategy rather than a reaction to immediate market conditions.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

This insider transaction is a routine disclosure and does not provide specific insights into broader industry trends or competitive landscape, beyond the general signal of management confidence.

Related Party Transactions

• Ilya M. Rachman, the CEO and Chairman, purchased 746 shares of Immix Biopharma common stock, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the CEO's purchase as a positive signal, potentially boosting investor confidence in the company's leadership and future prospects.

Key Dates

Recommendation

While an insider purchase by the CEO and Chairman is generally a positive signal, indicating management's confidence in the company, the relatively small number of shares acquired (746 shares) in the context of total beneficial ownership (1,141,683 shares) and the transaction being part of a pre-planned 10b5-1 program suggest it may not be a strong catalyst for a 'buy' recommendation. It reinforces a 'hold' position, acknowledging management's alignment with shareholder interests without indicating a significant new development.

Keywords

Immix Biopharma, IMMX, insider trading, Form 4, stock purchase, CEO, director, beneficial ownership, Rule 10b5-1